Vetter advances syringe closure technology with next-generation system
Vetter Pharma has unveiled its V-OVS® next syringe closure system, evolving their proprietary technology based on real-world clinical feedback. The updated design promises enhanced functionality, improved handling, and intuitive opening mechanisms while maintaining stringent product integrity standards for sterile injectables.
Enhanced design features prioritise clinical usability
The next-generation closure system incorporates several technical advances guided by shifting market requirements and customer experience. Maintaining the gold-standard Luer Lock features of the original system, V-OVS next introduces an improved tamper-evident design with enhanced user-friendliness specifically optimised for healthcare professionals.
“With its proprietary tamper-evident features, we’re confident that V-OVS next will bring a new level of user-friendliness to Luer Lock applications,” says Tobias Nemeth, Director Primary Packaging Service & Projects at Vetter. “It will further build on the decades of market impact delivered by this industry-leading system, and provide a differentiating choice for customers with an even wider range of injectable products.”
Technical refinements address practical clinical challenges
The refined closure features a more compact footprint to accommodate smaller syringe sizes, addressing an important need in specialised therapeutic areas. Ergonomically designed gripping surfaces provide improved control during the opening process, while an enhanced locking mechanism ensures secure placement even in demanding clinical environments.
These modifications directly respond to human factors studies conducted with frontline clinical users, whose feedback has been instrumental in finalising the design specifications. The company reports consistently positive responses from these evaluations, which will inform the final commercialisation phase.
Dual-system strategy preserves options for pharmaceutical partners
Vetter has established a launch timeline targeting 2027 for the V-OVS next system. Following introduction, the company plans to maintain both the original V-OVS and the next-generation closure in their portfolio, providing pharmaceutical partners with expanded options for their injectable product lines.
As a Contract Development and Manufacturing Organisation (CDMO), Vetter provides comprehensive services across the pharmaceutical development lifecycle. The company supports global pharmaceutical and biotechnology firms with drug product development, clinical and commercial filling, and assembly and packaging services for various injectable delivery systems.
The German-headquartered organisation maintains production facilities in Germany, Austria, and the United States, with additional sales operations throughout Asia-Pacific regions including Japan, China, South Korea and Singapore. Vetter emphasises its commitment to sustainability through participation in the UN Global Compact and Science Based Target initiative, having received gold status in EcoVadis rankings.
- For more information, visit vetter-pharma.com
